WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 15, 2005--OXiGENE, Inc. Principal Investigator Provides Interim Update to Clinical Trial; Data Shows Additional Responders in Patients with Advanced Ovarian Cancer. CA4P in Combination with Chemotherapy is Well Tolerated; No Drug-Related Serious Adverse Events or Cardiac Toxicities Observed. Dosing Regimen Established for Phase II Clinical Trial in Platinum-Resistant Ovarian Cancer.
